Biogen CEO Stepping Down

Biogen Inc (NASDAQ:BIIB)'s Chief Executive Officer Michel Vounatsos is stepping down after the unwanted incident takes place.

Biogen is grappling with Medicare proscribing protection for its Alzheimer's drug Aduhelm to patients in medical trials.

Biogen grappling with Medicare

Biogen CEO Vounatsos will Continue till

Vounatsos, who will proceed in his position till his successor is appointed, was named because the CEO in 2016

Biogen developed and launched a number of flagship medication together with spinal muscular atrophy drug Spinraza & Aduhelm.

Biogen- Drugs developed by the Company

Biogen to limit Alzheimer Drug

Biogen considerably eliminating commercial infrastructure associated to the Alzheimer's drug.

Biogen was betting on Aduhelm, the primary new remedy for the memory-robbing illness in almost 20 years

Biogen betting on Aduhelm

Biogen testing 2nd Alzheimer Drug

Biogen is now relying on its second Alzheimer's drug lecanemab, which like Aduhelm developed with Japanese Firm

Biogen shares are down 13% from the beginning of the year and are trading at $207.32 , down-from-52-week-high.

Biogen Company Shares

Biogen CEO Stepping Down- Swipe Up!!!

Swipe Up for More WebStories related to Technology, Finance, Gaming, Gadgets Review, & Other Trending News.